Anika reports fourth quarter and full year 2024 financial results

Full year 2024 results in line with guidance with commercial channel revenue up 17% strong international oa pain management and greater than 40% sequential growth of integrity™ implant system drive commercial channel growth and 2024 results key regulatory and clinical milestones achieved for hyalofast®, cingal®, and integrity strategic sale of parcus medical complete; resources refocused on programs positioned to generate significantly higher returns bedford, mass., march 12, 2025 (globe newswire) -- anika therapeutics, inc. (nasdaq: anik), a global leader in the osteoarthritis ("oa") pain management and regenerative solutions space focused on early intervention orthopedics, today announced financial results for the fourth quarter and full year ended december 31, 2024.
ANIK Ratings Summary
ANIK Quant Ranking